#TLM2024 #TARGETNASH
impact of GLP-1 on clinical outcomes in #cirrhosis

non-GLP-users:
⬆️ decomp HR 1.69
⬆️ mortality HR 2.28

💪 large, real world, clinical

➡️ lingering questions:

- role of muscle mass changes & outcomes in GLP users?

- is lack of GLP a marker for lack of access?

#liversky